Intersection of inflammation and herbal medicine in the treatment of osteoarthritis by Mobasheri, Ali
COMPLEMENTARYAND ALTERNATIVE MEDICINE (SL KOLASINSKI, SECTION EDITOR)
Intersection of Inflammation and Herbal Medicine
in the Treatment of Osteoarthritis
Ali Mobasheri
Published online: 18 September 2012
# The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract Herbal remedies and dietary supplements have
become an important area of research and clinical prac-
tice in orthopaedics and rheumatology. Understanding
the risks and benefits of using herbal medicines in the
treatment of arthritis, rheumatic diseases, and musculo-
skeletal complaints is a key priority of physicians and
their patients. This review discusses the latest advances
in the use of herbal medicines for treating osteoarthritis
(OA) by focusing on the most significant trends and
developments. This paper sets the scene by providing a
brief introduction to ethnopharmacology, Ayurvedic
medicine, and nutrigenomics before discussing the sci-
entific and mechanistic rationale for targeting inflamma-
tory signalling pathways in OA by use of herbal
medicines. Special attention is drawn to the conceptual
and practical difficulties associated with translating data
from in-vitro experiments to in-vivo studies. Issues re-
lating to the low bioavailability of active ingredients in
herbal medicines are discussed, as also is the need for
large-scale, randomized clinical trials.
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Introduction
The global incidence of age-related diseases of bone, joint, and
muscle is steadily rising, seriously affecting the health of
millions of people across the world. According to the United
Nations (UN) [1] and the World Health Organization (WHO)
[2] musculoskeletal, rheumatic, and arthritic conditions are
leading causes ofmorbidity and disability throughout the world,
and result in enormous healthcare expenditure and loss of work
[3] (sources: The Arthritis Foundation (AF) and WHO [4–6]).
The most common and important form of arthritis is osteoar-
thritis (OA), also known as osteoarthrosis or degenerative joint
disease (DJD). OA is the most common type of degenerative
joint disease. It is the major cause of pain and disability affect-
ing the elderly [7]. A 2005 study in the USA estimated that OA
is one of the top five causes of disability amongst non-
hospitalized adults (source: Centers for Disease Control and
Prevention, USA (CDC) [8]). According to estimates from the
National Institute of Arthritis and Musculoskeletal and Skin
Diseases (NIAMS) more than 20 million Americans currently
suffer from OA [9]. In 2006, it was estimated that around 35 to
40million Europeans had OA. It is expected that by 2030, 20%
of adults will have developed OA inWestern Europe and North
America. Therefore, OA is expected to be a heavy economic
burden on healthcare systems and community services in
Europe and the rest of the world.
Advancing age is a major risk factor for development of
OA. There is radiographic evidence of OA in at least one
joint in most of the human population aged 65 or over.
Although OA is rare in people under 40, it becomes much
more common with age. The end stage treatment for OA is
surgery, either to modify or replace the joint. With increas-
ing life expectancy, growth of the elderly population, and an
alarming escalation of chronic, inflammatory, and age-
related conditions (for example OA), there is increased
demand for new treatments and preventative approaches.
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Although OA is primarily associated with aging, there are
other important contributing factors [10]. These include genet-
ics, underlying anatomical and orthopaedic disorders (i.e. con-
genital hip dislocation), obesity, underlying inherited or
acquired metabolic disease, endocrine disease, various disor-
ders of bone turnover and blood clotting, joint infection, crystal
deposition, previous rheumatoid arthritis (RA) or a history of
joint trauma, repetitive use, muscle weakness, or joint instabil-
ity. The mechanical and metabolic alterations that occur in
obesity, with the pro-inflammatory factors produced by white
adipose tissue in the chronically overweight, are thought to be
major factors in the progression of the disease [11].
Symptoms of OA in the most frequently affected joints
include pain, stiffness and limited mobility, swelling, and, occa-
sionally, warmth. These manifestations are highly variable,
depending on joint location and disease severity. OA can affect
any synovial joint but it commonly affects large load-bearing
joints such as the hip and knee. The disease is often thought of as
being a result of daily wear and tear of the joint and, indeed, the
accumulation of microtrauma to cartilage and bone contribute to
pathogenesis. The most prominent anatomical feature is the
progressive destruction of articular cartilage [12]. However,
OA is a disease involving not only articular cartilage but also
the synovial membrane, subchondral bone, and peri-articular
soft tissues [13]. Inflammation of the synovium occurs in both
the early and late phases of OA and is associated with alterations
in the adjacent cartilage. This inflammatory synovitis is qualita-
tively highly similar to that seen in RA. Catabolic and proin-
flammatorymediators, for example cytokines, nitric oxide (NO),
prostaglandin E2 (PGE2), and neuropeptides are produced by the
inflamed synovium and alter the balance of cartilage matrix
degradation and repair. These events lead to excess production
of the proteolytic enzymes responsible for cartilage breakdown
[14]. Cartilage alterations induce further synovial inflammation,
creating a vicious circle. The progressing synovitis will then
exacerbate clinical symptoms and joint degradation in OA [14].
This article is a narrative review of herbal medicines for OA
and the challenges and opportunities facing this area of re-
search. Although most of the focus is on OA, the material
discussed is also relevant to other types of rheumatic disease
and musculoskeletal complaints for which pathogenic mecha-
nisms of different conditions overlap. This paper summarizes
the personal views and perspectives of a basic scientist working
in the area of cartilage biology and inflammatory signalling in
chondrocytes. For thousands of years human beings have used
and refined herbal medicines for treatment a variety of inflam-
matory diseases. Many ancient civilizations and cultures used
herbal extracts for their medicinal effects. Indeed, many of the
anti-inflammatory drugs in our current pharmacopoeia have
long established roots in ethnopharmacology (Fig. 1). This
paper will review the most up-to-date information and current
trends and topics in this area. The author has tried to make the
review as mechanistic as possible, highlighting the scientific
rationale for targeting inflammatory pathways in osteoarthritis
(OA) by use of herbal medicines. This article will also attempt
to draw attention to the conceptual and practical difficulties
associated with translating data from in-vitro models. Many
naturally occurring anti-inflammatory compounds in plants
are poorly absorbed in the gastrointestinal tract or rapidly
metabolized and excreted by the liver and the kidneys resulting
in low bioavailability. Consequently, in-vivo data and large-
scale, randomized clinical trials supporting the theoretical rea-
sons for using herbal medicines are largely lacking.
Why Do We Use Herbal and Complementary
Medicines?
There is currently no effective pharmacotherapy capable of
restoring the original structure and function of the damaged
cartilage and other synovial tissues in OA or, indeed, any
other form of arthritis. Apart from analgesics, limitations to
conventional medical management of OA indicate a genuine
need for novel, safe and effective treatments for OA
patients. Herbal medicines have the potential to provide a
solution to this problem.
The growing interest in herbal medicines and nutraceuticals
may reflect a general and increasing disenchantment with tra-
ditional medicine. This could be because of several factors:
conventional treatment may not be working as well as patients
would like; patients want greater relief of symptoms and/or
disability; they have issues with side-effects of pharmaceutical
treatment; they wish to reduce some of the stress that comes
from living with a chronic illness and want to cope better; they
believe that herbal and complementary therapy is safer and
more “natural”; and they are influenced by the widespread
advertising and attractive claims that are made for many natural
Fig. 1 Venn diagram indicating the overlap between conventional and
herbal medicines in the treatment of arthritic, rheumatic, and muscu-
loskeletal diseases. Some of the drugs in our pharmacopoeia (or their
derivatives) have a long established history in ethnopharmacology and
have been used for centuries
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products. Another reason why people use herbal and comple-
mentary medicines could be the corruption and gradual degra-
dation of the classic patient–physician relationship by
“managed care” and other cost cutting trends in the practice of
medicine. With chronic and incurable diseases, for example
OA, there can be considerable frustration at the inability of
modern scientific medicine to treat the disease. Consequently,
there is an increase in the patient-driven search for alternative
treatments.
Ethnopharmacology
Ethnopharmacology is the systematic study of the use of
herbal and medicinal plants by specific cultural groups. As a
discipline, ethnopharmacology is new and rapidly develop-
ing. Today, it is used to designate a field of specialization
that focuses on medicinal, psychoactive and toxic plants,
fungi, or even animals that are used by people all over the
world, and for research on nutraceuticals and food supple-
ments. The ethnopharmacological approach is unique in
pharmacology and the natural sciences in that it also
requires input from the social and cultural sciences. In
summary, ethnopharmacology is a multidisciplinary and
expanding field of study with its own scientific society
(The International Society for Ethnopharmacology [15])
and peer-reviewed scientific journals dedicated to the disci-
pline [16, 17].
Ayurvedic Medicine
Ayurvedic medicine (also called Ayurveda) is one of the
world’s oldest medical systems. It originated on the Indian
subcontinent and has evolved there for thousands of years.
In the United States, Ayurvedic medicine is considered to be
a Complementary and Alternative Medicine (CAM). It
includes the use of herbal medicines, massage, and special-
ized diets alone or in combination. Ayurvedic medicine may
involve the use of products such as spices, herbs, vitamins,
proteins, minerals, and metals (e.g., iron, zinc), often in
mixtures prepared for the individual patient. The products
are commonly sold on the Internet or in stores and are
represented as “Indian” or “South Asian”. However, con-
sumers should be aware that Ayurvedic products are not
reviewed or approved by the US Food and Drug Adminis-
tration (FDA [18]) before marketing. Most Ayurvedic prod-
ucts are marketed either for drug uses not approved by FDA
or as “dietary supplements”. Consumers should be especial-
ly cautious when purchasing these products on the Internet,
because the presence of metals such as lead, mercury, or
arsenic in some Ayurvedic products makes them potentially
very harmful [19].
“Nutrigenomic” Treatments for OA
Nutrigenomics is the study of the effects of foods and food
constituents on gene expression [20]. This field of study has
emerged because of the realization that the health effects of
food-derived substances start at the molecular level [20, 21].
Therefore, nutrigenomics is a form of personalized nutrition
that involves designing diets to fit an individual’s genetic
makeup, considering genetic variation, allergies, and intol-
erances [22]. Changes in gene expression result in changes
in the proteome and metabolome and, consequently, result
in an altered metabolic state, which may have beneficial
health effects. An important objective of nutrigenomic re-
search is defining the relationship between genes and
nutrients from basic biology to clinical states. We often
overlook the fact that nutrigenomics and systems biology
apply the same set of tools and technology. Systems biology
approaches are applied in nutritional research to describe the
physiological responses of culture models, experimental
animals, and human subjects by exploiting datasets which
focus on biochemical pathways, molecular targets for ther-
apy, and potential biomarkers. The nutrigenomics approach
extracts relevant differences, which become leads for further
hypothesis-driven and mechanistic research. One of the
objectives of research into herbal and alternative medicines
is to optimize health and prevent or delay disease
[23••]. Research that targets specific aspects of the main
drivers of health (metabolism, oxidation, inflammation,
and stress responses) may be instrumental in creating
knowledge for maintaining health and preventing dis-
ease through nutrition [23••].
Proinflammatory Cytokines in OA
Osteoarthritis (OA) is characterized by degeneration of ar-
ticular cartilage, limited intra-articular inflammation with
synovitis, and changes in peri-articular and subchondral
bone [13]. Proinflammatory cytokines are major mediators
of inflammatory responses. These proteins are intimately
involved in the pathogenesis of OA [13]. They cause syno-
vial, cartilage and bone changes during disease progression.
Proinflammatory cytokines are mainly produced in the
synovium, predominantly by the synovial macrophages that
drive the inflammatory and destructive responses in OA
[24]. These cytokines are thought to diffuse through the
synovial fluid into the cartilage where they stimulate chon-
drocytes and synoviocytes to increase cytokine production
and the production of degradative proteases. The intimal
cells of the synovium are most significant in the production
of cytokines that cause inflammation [25]. The main proin-
flammatory cytokines involved in the pathogenesis of OA
are TNF-α and IL-1β, which act on synoviocytes and
606 Curr Rheumatol Rep (2012) 14:604–616
chondrocytes via specific interactions with cytokine recep-
tors on the cell surface. These receptors include the IL-1β
receptor, the IL-1 receptor type I, the TNF-α receptor, and
the TNF-R55 receptor, which are highly expressed in syno-
vial fibroblasts [13, 26].
Proinflammatory Signalling and Activation of NF-κB
NF-κB (nuclear factor-κB) is a rapidly acting primary tran-
scription factor involved in cellular responses to inflamma-
tion and stress. In OA, NF-κB can be initiated by a host of
stress-related stimuli, including proinflammatory cytokines,
excessive mechanical stress, and extracellular matrix degra-
dation products [27••]. In unstimulated cells, NF-κB dimers
are sequestered inactively in the cytoplasm by a protein
complex called inhibitor of κB (IκB). IκB inactivates NF-
κB by masking the nuclear localization signals (NLS). Ac-
tivation of NF-κB occurs via degradation of IκB, a process
that is initiated by its phosphorylation by IκB kinase (IKK).
Phosphorylated IκB becomes dissociated from NF-κB,
unmasking the NLS. Phosphorylation also results in IκB
ubiquitination and targeting to the proteasome. Once phos-
phorylation of IκB and unmasking of the NLS has occurred,
NF-κB enters the nucleus to regulate gene expression. NF-
κB turns on expression of IκB, forming a negative feedback
loop. Targeted strategies to prevent unwanted or excessive
NF-κB activation are the focus of current OA research.
Work in this area is focused on the use of highly specific
drug modalities, small interfering RNAs (siRNAs), or other
biological inhibitors [27••]. Some of these biological inhib-
itors may come from natural products, plants, or herbs. It
has been suggested that targeting NF-κB in OAwill need to
consider the undesirable systemic effects of synthetic drugs
[27••].
Naturally Occurring NF-κB Inhibitors
Currently available drugs for OA are associated with un-
wanted side effects and are expensive. Naturally occurring
compounds capable of blocking NF-κB may be promising
therapeutic agents for treatment of OA. In recent years, there
has been a significant increase in the application of nutrige-
nomics in biomedical research. This has resulted in substan-
tial growth in phytopharmacology and renewed interest in
naturally occurring plant-derived compounds as potential
therapy for a variety of immune-related conditions. Several
herbal medicines have been investigated for their anti-
inflammatory and indirect MMP inhibitory capabilities.
These include phytochemicals and flavonoids and catechins
from green tea, rosehip, curcumin, and resveratrol (reviewed
in Ref. [28]).
Rosehip (Rosa canina)
Rosehip powder is extracted from the seeds and husks of the
fruits of a sub-type of Rosa canina and has been used exten-
sively in traditional medicine in tea, taken 3 or 4 times per day.
Rosehip powder also contains substantial amounts of vitamin
C. In-vitro, rosehip preparations have anti-inflammatory and
anti-oxidative properties, and have been shown to inhibit ex-
pression of iNOS, IL-1α and MMP-9, and IL-1β-induced
ADAMTS-4, MMP-1, MMP-13, IL-1α, and IL-8 in chondro-
cytes. The likely mechanism of action is via the specific gal-
actolipid constituent. One proprietary preparation of this
glycoside of mono and diglycerol is now a patented compound
that claims to temporarily relieve arthritic pain. A meta-analysis
of randomized controlled trials (RCTs) of a Rosa canina
(rosehip) powder preparation for symptomatic treatment of
OA was carried out to estimate its empirical efficacy as a
pain-reducing compound [29]. Although the effect size was
small, the meta-analysis revealed that rosehip powder does
reduce pain and results in a statistically significant reduction
in the use of analgesics. The study concluded that although the
efficacy and safety of rosehip needs evaluation and independent
verification, a large-scale/long-term clinical trial is justified
[29]. This study led to a recently registered clinical trial (Clin-
icalTrials.gov Identifier: NCT01430481 [30]) entitled: “Rose-
hip Powder for Knee Osteoarthritis” at the Frederiksberg
University Hospital in Denmark to compare two different rose-
hip products, one of which is tested in two different doses, in a
non-inferiority design. The clinical trial is an interventional
(parallel assignment), randomized, double blind safety and
efficacy study comparing different preparations and dosages
of rosehip powder in patients with painful knee OA.
Curcumin
Curcumin (diferuloylmethane) is a polyphenol phytochemical
found in the spice turmeric, derived from rhizomes of the plant
Curcuma longa. Turmeric has been used inAyurvedic medicine
for heartburn (dyspepsia), stomach pain, diarrhoea, intestinal
gas, stomach bloating, loss of appetite, jaundice, liver problems,
and gallbladder disorders. Curcumin has been shown to have
potent antioxidant, anti-inflammatory, and anti-catabolic
effects. It has been used as an anti-inflammatory treatment in
traditional Chinese and Ayurvedic medicine. We recently
reviewed the biological action of curcumin on cartilage and
articular chondrocytes [31•]. Curcumin antagonizes crucial cat-
abolic effects of IL-1β signalling that are known to contribute to
the pathogenesis of OA. Research in our laboratory has shown
that curcumin protects chondrocytes from the catabolic effects
of IL-1β, including upregulation of MMP-3 and suppression of
matrix synthesis [32]. IL-1β suppresses type II collagen and
β1-integrin synthesis in chondrocytes but these can be inhibited
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by curcumin [33]. Curcumin can also antagonize IL-1β-
induced caspase-3 activation in chondrocytes. Closer exami-
nation of the effects of curcumin on inflammatory signalling
in chondrocytes has revealed that this phytochemical can
suppress IL-1β-induced NF-κB activation, leading to inhibi-
tion of expression of cyclooxygenase-2 (COX-2) and matrix
metalloproteinase-9 (MMP-9) in articular chondrocytes [34].
Curcumin also suppresses glycosaminoglycan (GAG) release
in IL-1β-stimulated cartilage explants [35]. Collectively, these
results indicate that curcumin is a safe and promising herbal
medicine for treatment of OA. However, its efficacy and
bioavailability must be studied in greater detail in-vivo.
Work by Funk and colleagues [36] has demonstrated that
turmeric extracts containing curcuminoids (compounds related
to curcumin in structure and function) can prevent experimental
RA. The authors used the streptococcal cell wall (SCW)-in-
duced arthritis model, a well-described animal model of RA.
Arthritic index, a clinical measure of joint swelling, was used as
the primary endpoint for assessing the effect of extracts on joint
inflammation. An essential oil-depleted turmeric fraction con-
taining 41 % of the three major curcuminoids was found to be
efficacious in preventing joint inflammation when treatment
was started before, but not after, the onset of joint inflammation.
Interestingly, a commercial sample containing 94% of the three
major curcuminoids was even more potent in preventing arthri-
tis than the essential oil-depleted turmeric fraction when com-
pared by total curcuminoid dose per body weight. The authors
concluded that the three major curcuminoids present in the
purer form are responsible for this antiarthritic effect, whereas
the remaining compounds in crude extracts of turmeric may
inhibit this protective effect. This study emphasised that signif-
icantly different results and observations may arise from studies
that use crude extracts of turmeric and those that focus on
chemically purer forms of curcumin.
There are some concerns about the cytotoxicity of curcu-
min in culture models of cartilage [37]. However, the concen-
trations used in these studies are significantly higher than the
maximum concentration that can be achieved in serum and
synovial fluid after a large oral dose [31•]. Moreover, the
cytotoxicity data comes mainly from the C-28/I2 cell line,
which is an immortalized chondrocyte cell line. The curcumin
cytotoxicity observed in a transformed and immortalized
chondrocyte cell line does not necessarily indicate that this
compound will be toxic to untransformed primary cells and
chondrocytes within articular cartilage in-vivo [38, 39••].
Resveratrol
Resveratrol is a polyphenolic phytoalexin present in grapes,
berries, and peanuts. It has been reported to have anti-
inflammatory, immunomodulatory, and anti-oxidative prop-
erties. In-vitro, resveratrol has been shown to inhibit IL-1β-
induced apoptosis in chondrocytes, by inhibition of caspase-
3, and downregulation of the NF-κB pathway [40–43].
Resveratrol has also been shown to suppress NF-κB-
dependent pro-inflammatory products, for example PGE2,
leukotriene B4 (LTB4), COX-2, MMP-1, MMP-3, and
MMP-13. These results suggest the use of resveratrol as an
herbal medicine for treatment of OA. However, no random-
ized clinical trials have yet been conducted to test the in-
vivo efficacy and safety of resveratrol.
Synergistic Chondroprotective Effects of Curcumin
and Resveratrol
Recent studies from our laboratories have focused on the
synergistic anti-inflammatory effects of curcumin and resver-
atrol when used in combination. These studies have revealed
that mixtures of these phytochemicals may be more effective
than the individual compounds. Treatment with curcumin and
resveratrol suppresses expression of the NF-κB-regulated
gene products involved in inflammation (i.e. COX-2, MMP-
3, MMP-9, and vascular endothelial growth factor (VEGF))
[41]. Combinations of curcumin and resveratrol inhibit apo-
ptosis and prevent activation of caspase-3 [41]. Closer exam-
ination of the signalling pathway has shown that IL-1β-
induced NF-κB activation can be suppressed directly by mix-
tures of curcumin and resveratrol, by inhibition of Iκκ and
proteasome activation, inhibition of IκBα phosphorylation
and degradation, and inhibition of nuclear translocation of
NF-κB. On the basis of these results, we have proposed that
combining these natural compounds may be a more useful
strategy in developing herbal medicines than using the indi-
vidual compounds alone.
Combining curcumin and resveratrol also activates MEK/
Erk signalling. The mitogen-activated protein kinase
(MAPK) pathway is stimulated in differentiated chondro-
cytes and is an important signalling cascade for maintenance
of the chondrocyte phenotype. Activation of this pathway is
thought to be required for the maintenance of chondrocyte
differentiation and survival. These observations support the
enhanced potential of combination therapy, with both anti-
inflammatory and anti-apoptotic capabilities via inhibition
of multiple components of the NF-κB pathway, to treat OA.
Clearly, the concept of synergism in herbal medicine will
continue to be relevant to phytopharmacology.
Effects of Curcumin and Resveratrol on Mesenchymal
Stem Cells
Mesenchymal stem cells (MSCs) are a heterogeneous subset
of stromal cells that can be isolated from many adult tissues
[44]. Adult MSCs can be isolated from bone marrow,
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marrow aspirates, skeletal muscle, adipose tissue, synovium
and many other connective tissues [45]. Because of their
culture-dish adherence, they can be expanded in culture
while maintaining their multipotency [46]. Their multipo-
tency is an important property that enables them to differ-
entiate into cells of the mesodermal lineage, giving rise to a
range of specialized connective tissue cells, including adi-
pocytes, osteoblasts, chondrocytes, and tenocytes, and cells
of other embryonic lineages [44]. MSCs are currently being
clinically investigated as a new therapeutic for treating a
variety of immune-mediated diseases [47]. Thus, they have
potential applications in tissue engineering and regenerative
medicine and may be an attractive option for bone, cartilage,
tendon, and ligament regeneration.
Growth factors and a three-dimensional high-density cul-
ture environment are important for the differentiation ofMSCs
into chondrocytes, tenocytes, and osteoblasts [48–52]. IL-1β
and TNF-α inhibit chondrogenesis by human MSCs via NF-
κB-dependent pathways [53]. Therefore, strategies that facil-
itate cartilage repair under these conditions may include use of
specific antagonists of IL-1β and TNF-α, or the targeting of
NF-κB. Some of our recent work suggests that curcumin and
resveratrol have the potential to promote chondrogenic and
osteogenic differentiation of MSCs by targeting NF-κB. For
example, treating MSC cultures with curcumin has been
shown to suppress NF-κB, thus establishing a microenviron-
ment in which the effects of pro-inflammatory cytokines are
antagonized [54]. This facilitates the chondrogenesis of MSC-
like progenitor cells co-cultured with primary chondrocytes
[54]. The use of this strategy in-vitro may support the regen-
eration of articular cartilage in cell-based cartilage-repair tech-
niques, for example autologous chondrocyte implantation
(ACI), because cell-based repair of lesions in articular carti-
lage will be compromised in already inflamed joints.
Resveratrol-mediated modulation of SirT-1 (a NAD(+)-depen-
dent histone deacetylase) and RUNX2 (a transcription factor
that encodes a nuclear protein with an Runt DNA-binding
domain) promotes osteogenic differentiation of MSCs [55].
Our work also suggests that acetylation/deacetylation of
RUNX2 is critical for osteogenic differentiation [55].
Systematic Reviews of Herbal Medicines
The effectiveness of herbal medicines in the treatment of
OA has been evaluated in a systematic review of random-
ized controlled trials of herbal medicines published by Long
and co-workers in 2001 [56]. Twelve clinical trials and two
systematic reviews fulfilled the authors’ inclusion criteria.
The authors found promising evidence of effective use of
some herbal preparations in the treatment of OA. In addi-
tion, evidence was found to suggest that some herbal med-
icines might actually reduce the consumption (and dosage)
of non-steroidal anti-inflammatory drugs. Many of the herb-
al medicines reviewed seemed to be relatively safe. The
authors concluded that some herbal medicines might be
realistic alternatives for patients with OA.
Another systematic review of herbal therapies for OA
was published in the same year by Little and Parsons [57],
in the Cochrane Database of Systematic Reviews. The
authors searched the databases for mainstream and comple-
mentary medicines and included any randomized trials of
herbal intervention that they could find related to OA (in any
language). Five studies on four different herbal interven-
tions met the review criteria. The authors were not able to
draw any firm conclusions from the single studies, but two
studies indicated avocado and soybean unsaponifiables had
beneficial effects on functional index, pain, NSAID con-
sumption, and global evaluation. The investigators conclud-
ed that the evidence in support of use of avocado–soybean
unsaponifiables for treatment of OA is convincing but that
there is not sufficient evidence for the other herbal interven-
tion for OA.
Soeken [58] examined the evidence from systematic
reviews assessing what is known about the efficacy of
selected CAM therapy for arthritis pain. Results specifically
related to arthritis pain were retrieved from review articles
on acupuncture, homeopathy, herbal remedies, and a select-
ed number of nutritional supplements. Evidence was found
to support the efficacy of herbal medicines including devil’s
claw and avocado and soybean unsaponifiables. This study
concluded that CAM therapy has potential but more high-
quality research is needed for herbal medicines.
These systematic reviews have stimulated further re-
search on herbal medicines for OA. This topic of OA re-
search is now a thriving and expanding “niche” area.
However, the presumption that herbal medicines are effec-
tive and safe is an issue that requires regular discussion and
debate, and tight regulation by relevant regulatory bodies.
According to the American College of Rheumatology, herb-
al remedies are not subjected to the same quality assurance
testing that is required for prescription drugs. This has raised
many concerns about the quality and safety of many of the
herbal medicines that originate in the Far East. The actual
contents of many herbal remedies do not necessarily match
the ingredients on their label. The biggest concern at the
moment is that herbal remedies can be quite toxic (or con-
tain specific toxic components) and can interact adversely
with prescription drugs.
Clinical Trials of Herbal Medicines
A prescription medical food product containing flavocoxid
and citrated zinc bisglycinate has been marketed for the
clinical dietary management of the metabolic processes of
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OA. It was developed and formulated specifically for patients
with OA. Although it is not a NSAID, nor a COX-2 selective
inhibitor, it is proposed to function as an anti-oxidant, and as a
dual inhibitor of the cyclooxygenase (COX) and lipoxygenase
(LOX) enzymes of arachidonic acid metabolism. Flavocoxid
consists primarily of the flavonoids baicalin and catechin.
These flavonoids are found in commonly consumed foods,
for example soy, peanuts, cauliflower, kale, apples, apricots,
cocoa, and green tea. The manufacturers claim that the prod-
uct provides flavonoid levels that are needed to meet the
distinctive nutritional requirements of OA patients. They also
claim that the flavonoid levels provided cannot be obtained by
simply changing the diet. A recently conducted clinical trial
(ClinicalTrials.gov Identifier: NCT00928837 [59]) entitled:
“Study of Flavocoxid (Limbrel) Versus Naproxen in Subjects
With Moderate-Severe Osteoarthritis of the Knee” has shown
the compound to have side effects comparable with placebo.
The primary and secondary outcome measures in this trial
included efficacy, safety, quality of life, and economic impact
compared with the NSAID naproxen and placebo.
A related article in this issue of Current Rheumatology
Reports will address the clinical trials that have been pub-
lished to date, emphasising the major drawbacks of these
studies. The general consensus is that most clinical trials
conducted to date have been inadequately powered and have
not been of sufficient length and duration.
PubMed Literature Survey
APubMed literature surveywas conduced on 4 July 2012 using
the keywords “herbal medicine” and “osteoarthritis”. This
search revealed a total of 88 papers in the PubMed. Selected
papers from this literature search are reviewed in this section.
In a double-blind study Mills et al. [60] studied the effects of
a proprietary herbal medicine on the relief of chronic arthritis
pain. Eighty-two subjects with chronic arthritis pain were ran-
domly assigned for two months without crossover to either a
product containing sarsaparilla, white willow bark, black co-
hosh, guaiacum resin, and poplar bark, a licensed over-the-
counter (OTC) herbal medicine, or a placebo. Questionnaires
revealed amild analgesic effect in subjects with chronic arthritis.
Ginger, which originates from the dried or fresh root of the
ginger plant, contains active ingredients that may have anal-
gesic and anti-inflammatory properties. Bliddal et al. [61]
conducted a randomized, placebo-controlled, crossover study
of ginger extract and ibuprofen in patients with hip or knee
OA. The effects of ginger extract were compared with placebo
and ibuprofen in a controlled, double blind, double-dummy,
cross-over study with a wash-out period of one week followed
by three treatment periods in a randomized sequence, each of
three weeks duration. As might be expected, the results of the
study revealed the following ranking of efficacy: ibuprofen>
ginger extract>placebo. No significant difference between
placebo and ginger extract could be demonstrated in the
crossover study. Statistically significant effects of ginger ex-
tract could only be demonstrated by complex statistical meth-
ods in the first period of treatment before crossover. No
significant difference was observed in the study as a whole.
The efficacy of Harpagophytum procumbens in the treat-
ment of knee and hip OAwas investigated in a double-blind,
randomized, multicentre clinical study [62]. The herbal med-
icine product was used at a dose of six capsules/day, each
containing 435 mg of cryoground and powdered Harpago-
phytum procumbens. This product was compared with diac-
erhein 100mg/day. Pain and functional disability were assessed
by use of a visual analogue scale (VAS) and the severity of OA
was evaluated by use of the Lequesne index. Although there
was no difference in the efficacy of the two treatments, at the
end of the study, patients taking the herbal product were using
significantly less NSAIDs. The authors concluded that the
herbal product was comparable with diacerhein in terms of
efficacy but superior to diacerhein in terms of safety.
Choi et al. tested the effects of the herbal agent SKI 306X
on proteoglycan degradation in rabbit cartilage explants in-
vitro and a collagenase-induced rabbit model of OA [63]. SKI
306X is an extract of three herbs: Clematis mandshurica,
Trichosanthes kirilowii, and Prunella vulgaris. The authors
compared the effects of this herbal extract with those of
dexamethasone and two NSAIDs, diclofenac and rofecoxib.
Recombinant human interleukin-1α was used to induce pro-
teoglycan (PG) degradation and the degree of PG degradation
was assessed by measuring the quantity of glycosaminogly-
cans (GAGs) released into the culture medium. In-vivo experi-
ments involved intra-articular injection of collagenase into the
right knee joint of rabbits to induce OA-like changes followed
by a histological examination after 28 days. SKI 306X
inhibited PG degradation in a concentration-dependent man-
ner. Interestingly dexamethasone, diclofenac, and rofecoxib
did not suppress PG degradation. In-vivo studies showed that
a 200-mg/kg dose of SKI 306X reduced OA-like histological
changes, whereas diclofenac had no effect at 10 mg/kg. The
authors concluded that the herbs in the SKI 306X extract have
chondroprotective effects in-vitro and in-vivo.
Kim et al. [64] extended the work on SKI 306X by inves-
tigating its gastro-sparing effects on the gastric mucosa. They
compared its effects with those of diclofenac, a conventional
NSAID, and celecoxib, a cyclooxygenase-2 (COX-2)-specific
inhibitor. To investigate the acute gastric damaging properties
of SKI306X, the stomachs of the animals were histologically
and immunohistochemically examined. Their results suggest
that SKI 306X suppresses gastric leukotriene B4 (LTB4) syn-
thesis without causing mucosal injury or diclofenac-induced
gastric lesions. SKI 306X did not have a significant effect on
the levels of prostaglandin E2 (PGE2). In addition, gastro-
protective effects of SKI306X were induced by suppressing
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diclofenac-induced erosion and ulceration of gastric mucosa
in a rat model, also by sparing the gastric mucosa by suppres-
sion of gastric leukotriene synthesis.
Teekachunhatean et al. [65] compared the Chinese herbal
recipe Duhuo Jisheng Wan (DJW), a combination product
containing Angelica pubescens and other plant extracts, with
diclofenac for the symptomatic treatment of knee OA. This
study was a randomized, double-blind controlled trial that
included 200 subjects suffering from knee OA. Patients were
evaluated after a run-in period of one week followed by weekly
evaluations during subsequent weeks of treatment. Clinical
assessments included VAS scores for pain and stiffness,
Lequesne’s functional index, time for climbing up 10 steps,
and physicians and patients’ overall opinions on improvement.
In the first few weeks of treatment, the mean changes in VAS
for walking pain, standing pain, and stiffness, and Lequesne’s
functional index of the DJW group were significantly lower
than those of the diclofenac group. However, the physicians’
and patients’ overall opinions did not significantly differ be-
tween the two groups and one third of patients in both groups
experienced mild adverse events. The authors concluded that
although DJW had clinical efficacy comparable with that of
diclofenac, the slow onset of action and the adverse effects
limited its clinical value as a treatment for knee OA.
Elegant studies by Wu et al. [66, 67•] have evaluated the
anti-inflammatory activity of an ethanolic extract of Caesalpi-
nia sappan in human chondrocytes and macrophages. Caesal-
pinia sappan is a common remedy in Traditional Chinese
Medicine and possesses diverse biological activities. In the first
study, the authors demonstrated the anti-inflammatory activity
of Caesalpinia sappan extracts in an in-vitro model of joint
inflammation.Caesalpinia sappan extracts inhibited the IL-1β-
induced over-expression of inflammatory mediators at the tran-
scriptional level in human chondrocytes and macrophages
[67•]. In a subsequent study published a year later, the authors
provided further molecular support for this observation [66].
They treated primary human chondrocytes (isolated from OA
cartilage), SW1353 chondrosarcoma cells, and THP-1 macro-
phages with IL-1β or lipopolysaccharide (LPS). Nitric oxide
(NO) and tumour necrosis factor-alpha (TNF-α) were evaluated
by use of theGriess assay and ELISA, respectively.Caesalpinia
sappan extracts dose-dependently inhibited expression of pro-
inflammatory cytokines IL-1β and TNF-α in IL-1β-stimulated
chondrocytes and LPS-stimulated THP-1 macrophages. Cae-
salpinia sappan extracts also suppressed the synthesis of NO in
primary OA chondrocytes by blocking iNOS mRNA expres-
sion. They observed that the levels of IL1β-induced MMP-1,
MMP-3, MMP-7, and MMP-9 mRNA, but not TIMP mRNA
levels, were down-regulated in chondrocytes in response to
Caesalpinia sappan extracts. Zymography suggested that Cae-
salpinia sappan extracts did not interfere with the proteolytic
activity of MMP-2. Interestingly, the inhibition of COX-2 tran-
scription by Caesalpinia sappan extracts was related to the
inhibition of the p65/p50-driven transactivation of the COX-2
promoter. The authors concluded that Caesalpinia sappan
extracts abrogate the IL-1β-induced over-expression of in-
flammatory mediators in human chondrocytes and macro-
phages. The most likely mechanism accounting for the anti-
inflammatory activity of Caesalpinia sappan extracts is inhi-
bition of NF-κB (p65/p50) signalling. The authors proposed
that blocking IL-1β-induced NF-κB signalling and its down-
stream pro-inflammatory targets by Caesalpinia sappan
extracts may reduce cartilage breakdown in arthritis.
Park and co-workers [68] examined the therapeutic effects
of PG201, an ethanolic herbal extract in a collagenase-induced
model of arthritis in rabbits. The right knees of rabbits were
injected intra-articularly with collagenase and the rabbits were
orally treated with distilled water, PG201 (200 mg/kg), or
diclofenac (10 mg/kg) once a day for 8 weeks. Administration
of PG201 significantly suppressed stiffness and joint space
narrowing. Cartilage destruction and GAG release were sub-
stantially reduced in the knee joints. Expression of matrix
metalloproteinases MMP-1, MMP-3, and MMP-13 was re-
duced by PG201. The levels of the inflammatory mediators
IL-1β, PGE2, and nitric oxide NO were also reduced by
PG201. The authors concluded that PG201 has therapeutic
effects in this animal model of arthritis.
A study byWang et al. [69] assessed the short-term efficacy
and safety of Traditional Chinese herbal patches, Fufang
Nanxing Zhitong Gao (containing, among other ingredients,
extracts of Rhizoma arisaematis, Radix aconite, and Flos
caryophylli) and Shangshi Jietong Gao, containing a 17-herb
mixture, for painful knee OA. Patients were randomly enrolled
in a double-blind, placebo-controlled study to receive the
herbal patches, or a placebo patch for seven days. Outcome
measures included VAS, Western Ontario, andMcMaster Uni-
versities Osteoarthritis Index (WOMAC), and the Traditional
Chinese Medicine Syndrome Questionnaire (TCMSQ) sub-
scale. The study found no significant differences among the
three groups in terms of short-term pain management.
Majima et al. [70] studied the effects of Boiogito, a Japa-
nese herbal medicine containing an anti-inflammatory com-
pound called sinomenin, on knee OA and joint effusion.
Patients were randomly assigned to two groups, one receiving
loxoprofen and Boiogito and the other group using loxoprofen
only. Outcomes were evaluated over 12 weeks using knee
scores and questionnaires. Knee scores was significantly im-
proved in the group receiving Boiogito and loxoprofen com-
pared with the loxoprofen only group. The authors concluded
that Boiogito may be a useful treatment for knee OA.
Finally, a recent study from our laboratory attempted to
characterize the anti-inflammatory mode of action of herbal
extracts from rosehip (Rosa canina), willow bark (Salix alba),
and nettle leaf (Urtica dioica) in an in-vitro model of primary
canine articular chondrocytes [71]. The extract of willow bark
has been used in traditional medicine as a pain reliever. The
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biological effects of the herbal extracts were studied in canine
chondrocytes treated with IL-1β. Expression of collagen type
II, proteoglycans, β1-integrin, SOX-9, COX-2, MMP-9, and
MMP-13 was examined by western blotting. The extracts sup-
pressed IL-1β-induced NF-κB activation by inhibition of
IκBα phosphorylation, IκBα degradation, p65 phosphoryla-
tion, and p65 nuclear translocation. These events correlated
with downregulation of NF-κB targets including COX-2 and
MMPs. The extracts also reversed the IL-1β-induced down-
regulation of collagen type II, cartilage-specific proteoglycans
(CSPGs), β1-integrin, and cartilage-specific transcription fac-
tor SOX-9 protein expression. We also used high-density cul-
tures to demonstrate that the herbal extracts can stimulate new
cartilage formation, even in the presence of IL-1β. The study
concluded that herbal extracts can exert potent anti-
inflammatory actions in-vitro and may have beneficial proana-
bolic effects on chondrocytes also. The observed reduction of
IL-1β-induced NF-κB activation provides more evidence for
natural targeting of NF-κB in arthritic diseases. In contrast to
our work, a 2004 study concluded that extracts of willow bark
have no relevant efficacy in patients with OA and RA [72].
Regulatory Considerations
Herbal and alternatives medicines and nutraceuticals are bold
challenges to government and state regulations. In 1992, the
National Institutes of Health (NIH) established an Office of
Alternative Medicine. The United States Congress subse-
quently elevated this to a Center for Complementary and
Alternative Medicine with a multi-million dollar annual
budget. Historically, the FDA [18] took the view that a prod-
uct that made health claims was a drug. Consequently, in the
1970s vitamins and minerals were exempted from regulation
as drugs as long as they did not make health claims. In the
early 1980s, studies demonstrated that some food ingredients,
for example fibre, provided specific benefits to health. Food
manufacturers wanted to proclaim these benefits to consumers
without having to obtain drug approval. The FDA wrestled
with this problem until the US Congress passed the Nutrition
Labeling and Education Act of 1990. This law authorized the
FDA to issue regulations permitting specific health claims for
foods, which led the agency to allow claims associating low
levels of calcium with osteoporosis, dietary fats with cancer,
and cholesterol with heart disease. After passage of the FDA
Modernization Act of 1997, a food could make a health claim
without FDA regulatory authority as long as the claim was
based on an authoritative statement by a governmental or
quasi- governmental scientific body (for example the NIH or
the National Academy of Science [NAS]) and the agency was
given advanced notice of the manufacturer’s intent. However,
this leeway did not apply to dietary supplements and so it has
resulted in much confusion. The presence of metals, for ex-
ample lead, mercury, and arsenic in some herbal remedies
makes them potentially very harmful. Furthermore, some of
the ingredients can interact with each other and with conven-
tional medications that patients may be taking.
The situation in Europe has been equally chaotic. Conse-
quently the European Food Safety Authority (EFSA) based in
Parma, Italy, has issued new guidelines and proposed new
scientific requirements for health claims related to the mainte-
nance of joints and to the reduction of the risk of developing
Fig. 2 Schematic diagram
summarizing some of the
effects of herbal medicines on
chondrocytes, synovial tissues,
and mesenchymal stem cells
(MSCs)
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OA. The EFSA has proposed that clinical trials of functional
foods and nutraceuticals should be designed in new and inno-
vative ways to demonstrate a “beneficial physiological effect”
on healthy joints. According to these new guidelines, only
clinical trials designed to demonstrate a beneficial physiological
effect on joints or a reduction in joint degradation in people
without OA should be accepted as indicative. These guidelines
present some major new challenges to the scientific and clinical
communities. Furthermore, they create a number of opportuni-
ties for new types of clinical trial. Studies performed in non-
diseased (but including high risk) population subgroups in
which the incidence of OA is the outcome measure could be
used for substantiation of health claims relating to the normal
maintenance of the joint. Whilst attempting to address these
requirements, we need to discriminate between food and non-
food supplements. Studies dealing with “non-foods” will re-
quire a much more traditional pharmacological design com-
pared with studies on “foods”. Clearly, addressing these issues
requires new strategies and large-scale clinical studies lasting
several decades. Such new trials will require radical rethinking
of the concept of clinical trials in the OA research community.
Human studies seem to be central to substantiation of clinical
data and study groups should be representative of the entire
population. Hierarchy of evidence is also considered; for exam-
ple, interventional studies are of greater significance than ob-
servational studies and reproducibility of the effect much be
demonstrated. In addition, demonstrating efficacy of food sup-
plements to the EFSA will also require data on tolerance and
safety, specifically gastric tolerance, hepatotoxicity, renal toxic-
ity, and allergenicity.
Hormetic Effects of Herbal Medicines
Herbal medicines may have beneficial effects at low concen-
trations as long as they are consumed over a long period of time.
Studying this aspect of their action may require longer-term
studies. The term “hormesis” is used to describe a biphasic
dose response to an environmental agent or chemical charac-
terized by stimulation or beneficial effects at low doses or
toxic and inhibitory effects at high doses. Hormesis is a
fundamental concept that applies to the almost all drugs
derived from plants and microorganisms. Even synthetic
drugs thought to act on a specific molecular target may exert
“off-target” or “hormetic” effects. The response of the cell or
organism to the low dose of a toxin is regarded as an adaptive
compensatory process after initial disruption in homeostasis.
Thus, a short working definition of hormesis is “a process in
which exposure to a low dose of a chemical agent or environ-
mental factor that is damaging at higher doses induces an
adaptive beneficial effect on the cell or organism”. The prev-
alence in the literature of hormetic dose responses to environ-
mental toxins has been reviewed comprehensively [73], as
have the implications of toxin-mediated hormesis for under-
standing carcinogenesis and its prevention [74]. Several dif-
ferent terms are commonly used to describe specific types of
hormetic responses including “preconditioning” and “adap-
tive stress response”. Hormesis in aging is defined as the life-
supporting beneficial effects resulting from the cellular
responses to single or multiple rounds of mild stress. Thus,
hormesis may also have the capacity to modify the ageing
process [75]. The dose–response relationships for herbal med-
icines commonly have the same hormetic dose–response rela-
tionships as their toxic counterparts. Many agents, for
example antibacterials, antifungals, antivirals, and tumour-
fighting drugs, have hormetic dose responses. Even curcumin
exerts a hormetic effects at the cellular and molecular levels in
mammalian cells [76]. Therefore, we need to consider the
potential long-term hormetic effects of herbal medicines.
Conclusions
Herbal remedies, and dietary supplements have become im-
portant areas of research and clinical practice in orthopaedics
and rheumatology [77]. Therefore, it is important that health-
care providers and patients are aware of the evidence for or
against these approaches [78]. Some of the published evidence
suggests that several herbal medicines and dietary supple-
ments have the capacity to alleviate the pain of OA and RA
[79]. For several treatments, the risk–benefit profile is encour-
aging. Some herbal remedies are inhibitors of NF-κB and may
be able to reduce the consumption of NSAIDs and stimulate
the differentiation of MSCs (Fig. 2). The author’s personal
view is that only some of the research on herbal medicines can
be defined as “rigorous”. A substantial proportion of the
published literature does not reach the required levels of
scientific rigor. For example, some studies on herbal and
traditional medicines have not included a placebo group
[80]. The first preliminary study on the anti-rheumatic activity
of curcumin suffered from fundamental weaknesses relating
to experimental design [81]. Many other studies suffer from
methodological limitations [82]. Clearly, more rigorous test-
ing of herbal remedies and complementary treatments should
be the main priority of future studies.
The main purpose of herbal and complementary medicines
is to supplement some of the benefits from existing pharma-
ceutical treatment modalities [83]. The objective is to reduce
the frequency of consumption and dosages of conventional
drugs, for example NSAIDs. The objective is not to replace
NSAIDs altogether because they not only provide pain relief,
but also have valuable anti-inflammatory activity. However,
elderly patients with OA routinely use prescribed and alterna-
tive products at the same time. There is potential for adverse
drug interactions and patients should be made aware of the
risks associated with taking multiple products [84].
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In summary, the elderly population is rapidly growing and
expanding throughout the developed and developing worlds.
Therefore, the use of herbal and complementary medicines for
treatment of persistent musculoskeletal pain will continue to
increase [85]. When we consider the popularity of herbal rem-
edies, more mechanistic basic studies should be encouraged as a
prelude to large-scale, randomized clinical trials. In addition,
basic common sense must prevail throughout this process. For
instance, is it realistic to propose that an herbal extract tested in-
vitro for inhibition of COX-2 can actually be effective when
ingested by human beings? Is it not prudent to consider gastro-
intestinal absorption, systemic processing, and bioavailability of
the active ingredient(s)? This is the only way to address the
mismatch betweenwhat we had hoped for with herbalmedicines
(efficacy with more safety and less toxicity) and what we actu-
ally have so far. This is why more rigorous clinical trials exam-
ining the efficacy of herbal remedies are needed before definitive
recommendations regarding the application of these modalities
can be made [85]. Our research efforts must be directed toward
defining the risk-to-benefit ratio for herbal and alternative med-
icines for specific musculoskeletal conditions [82].
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